Streetbeat News

Stock Prices

DYN

Dyne Therapeutics announced positive clinical data from its Phase 1/2 trials for DYNE-101 in Myotonic Dystrophy Type 1 and DYNE-251 in Duchenne Muscular Dystrophy. Both drugs showed significant improvements in key metrics and favorable safety profiles. The company is pursuing expedited approvals with updates expected by year-end.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:33 am

KITT

Nauticus Robotics, Inc. has entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC to sell shares of common stock. The company will pay a broker fee of 3% of the gross sales price of the shares sold.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:26 am

CARR

CCI

JCI

LII

NRG

ST

Elliott Investment Management has acquired a significant stake in Johnson Controls International (NYSE:JCI), valued at over $1 billion. This move comes as Johnson Controls' performance has lagged behind competitors like Carrier Global Corp. (NYSE:CARR) and Lennox International Inc. (NYSE:LII). The activist investor has a history of driving executive changes in its portfolio companies. Johnson Controls' shares are trading higher by 4.62% in premarket trading.

Portfolio Pulse from Shivani Kumaresan

May 20, 2024 | 10:24 am

SOBR

SOBR Safe has failed to meet the bid price requirement and is planning to challenge a potential delisting from the stock exchange.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:13 am

BA

China has imposed symbolic sanctions on Boeing Co. and other U.S. defense firms over arms sales to Taiwan. The sanctions are expected to have minimal impact on these companies as they do not conduct significant business in China.

Portfolio Pulse from Benzinga Neuro

May 20, 2024 | 10:09 am

CXW

Corecivic's board has authorized an increase to its existing share repurchase program, allowing the company to buy back up to an additional $125 million in shares.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:06 am

GUTS

Fractyl Health, Inc. (NASDAQ:GUTS) presented preclinical data from its Rejuva pancreatic gene therapy program at Digestive Disease Week 2024, focusing on a single-administration GLP-1 therapy for obesity and type 2 diabetes.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:04 am

ESPR

OTSKY

Esperion and Otsuka reported that the primary endpoint was achieved in a Phase 3 trial in Japan for bempedoic acid as a potential treatment for hypercholesterolemia. The trial showed statistically significant outcomes, with a -25.25% change in LDL-C at Week 12 for the bempedoic acid group compared to -3.46% for the placebo group. Otsuka holds exclusive development and commercialization rights for bempedoic acid in Japan.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:02 am

ARWR

Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented new interim clinical data on ARO-RAGE, showing significant gene knockdown in asthma patients. The data was shared at the ATS 2024 International Conference, highlighting dose-dependent reductions in sRAGE concentration in both healthy volunteers and asthma patients.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:02 am

BCLI

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) will present new biomarker data suggesting ALS patients may benefit from longer-term treatment with NurOwn at the 3rd Annual ALS Drug Development Summit in May 2024.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:01 am